Brooks Hill Partners Invests in Cellbricks

Brooks Hill Partners has invested in Cellbricks, a Berlin-based startup leveraging a novel suite of 3D bioprinting technologies to transform preclinical pharmaceutical research and clinical care. Cellbricks will soon enter preclinical trials for its 3D bioprinted personalized post-mastectomy breast reconstruction implant.

Learn more about Cellbricks here.

Brooks Hill Partners is a life sciences consultancy and early-stage health tech venture capital firm that partners with passionate companies across the biopharma and healthcare landscape. Please contact us to learn more about how we can help you today. For more information, visit https://www.brookshillpartners.com/ and follow us on LinkedIn.